Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benoxaprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CASP3 | P42574 | 5/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benoxaprofen SCHEMBL24413 | 1.00 | MAOA (1.00) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL24414 | 1.00 | MAOA (1.00) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL11246423 | 0.99 | MAOA (0.98) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL28038058 | 0.99 | MAOA (0.98) | MAOAADRA1ACASP3SENP7HDAC3 | |
| SCHEMBL12608959 | 0.93 | MAOA (0.86) | MAOAADRA1ACASP3SENP7HDAC3 | |
| SCHEMBL3196762 | 0.90 | MAOA (0.82) | MAOAADRA1ACASP3SENP7HDAC3 | |
| SCHEMBL11176670 | 0.90 | MAOA (0.82) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL6694507 | 0.89 | MAOA (0.80) | MAOAADRA1ACASP3SENP7HDAC6 | |
| SCHEMBL9706321 | 0.88 | MAOA (0.79) | MAOAADRA1ACASP3SENP7HDAC3 | |
| Benoxaprofen SCHEMBL7925364 | 0.88 | MAOA (0.77) | MAOAADRA1ACASP3SENP7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795141-B1 | SOLID SOLUTION COMPOSITIONS | INFIRST HEALTHCARE LTD (GB) | 2025-07-30 | — | — | EP | claimed |
| WO-2025132620-A1 | STABLE SOFT CAPSULE PREPARATIONS WITH SOLID FILL FOR MOISTURE SENSITIVE ACTIVE INGREDIENTS | BAYER CONSUMER CARE AG (CH) | 2025-06-26 | — | — | WO | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| EP-3773445-B1 | RETINOL REPLACEMENT IN SKIN TREATMENT | SYMRISE AG (DE) | 2024-07-24 | — | — | EP | claimed |
| WO-2024117797-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DRUG-RELATED PEPTIC ULCER COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 제일약품 주식회사 | 2024-06-06 | — | — | WO | claimed |
| EP-3796895-B1 | BIOMIMETIC VESICLES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-02-14 | — | — | EP | claimed |
| US-11844773-B2 | Solid solution compositions and use in chronic inflammation | INFIRST HEALTHCARE LIMITED (GB) | 2023-12-19 | — | — | US | claimed |
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | claimed |
| US-11730709-B2 | Compositions and methods for treating severe pain | INFIRST HEALTHCARE LIMITED (GB) | 2023-08-22 | — | — | US | claimed |
| US-11660276-B2 | Compositions and methods for treating chronic inflammation and inflammatory diseases | INFIRST HEALTHCARE LIMITED (GB) | 2023-05-30 | — | — | US | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220110979-A1 | FIBROBLAST REGENERATIVE CELLS | FIGENE, LLC | 2022-04-14 | — | — | US | claimed |
| US-20260117177-A1 | T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | DARTMOUTH COLLEGE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4719353-A1 | REVERSIBLE SURFACTANT AND MULTIFUNCTIONAL DRUG DELIVERY SYSTEMS BASED THEREON | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-04-08 | — | — | EP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| WO-2022032044-A2 | MULTI-REFERENCE POLY-CONFORMATIONAL COMPUTATIONAL METHODS FOR DE-NOVO DESIGN, OPTIMIZATION, AND REPOSITIONING OF PHARMACEUTICAL COMPOUNDS | QUANTORI LLC (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-02-10 | — | — | US | disclosed |
| US-20220040102-A1 | Solid Solution Compositions and Use in Chronic Inflammation | INFIRST HEALTHCARE LIMITED (GB) | 2022-02-10 | — | — | US | disclosed |
| WO-2022020756-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND ANXIETY DISORDERS | MANSELL JOHN (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117177-A1 | T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | ICOS, CD4, CD2 | MAOA 4815/4885ADRA1A 3429/4885CASP3 1401/4885 |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | MAOA 2606/4885ADRA1A 2369/4885CASP3 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.